Why Generics Cost Less Than Brand-Name Medicines

A common instinct when comparing two boxes on a pharmacy shelf is that the cheaper one must be worse. With medicines, that instinct is usually wrong — and the reasons are worth understanding, because they also explain when a low price genuinely is a warning sign.

The cost of being first

Developing a new medicine is expensive. The originator company funds discovery work, laboratory studies, multiple phases of clinical trials, regulatory submissions in every market, and the entire cost of failures — the many candidate compounds that never reach approval. Those costs are recovered from the products that do.

To make that possible, a new medicine is protected by patents for a period. During that time the originator is the only lawful supplier, and the price reflects both the investment and the absence of competition.

What happens at patent expiry

When patent protection ends, other manufacturers may apply to supply the same active ingredient. They still have to satisfy the TGA — demonstrating bioequivalence and meeting good manufacturing practice standards before the product is entered on the ARTG — but they do not have to repeat the original discovery programme or the full clinical development.

That is the single biggest driver of the price difference. The generic manufacturer's costs are manufacturing, quality assurance, regulatory work and distribution. They are not zero, but they are far smaller than the cost of inventing the medicine in the first place.

The other contributors

Several smaller factors push the same direction:

• No brand marketing. The originator spent years building recognition of a brand name. Generic manufacturers generally do not.
• Competition. Once several manufacturers supply the same ingredient, price competition follows. This is why prices in a category often keep falling for years after the first generic arrives.
• Manufacturing scale and simpler packaging. Plain packaging and larger production runs cost less per unit.
• Established formulation science. The formulation and stability work has already been mapped out by the original product.

Where the PBS fits in

For medicines subsidised under the Pharmaceutical Benefits Scheme, the price you pay at the counter is shaped by the co-payment structure rather than the manufacturer's price alone. Policy mechanisms including price disclosure have progressively reduced what the scheme pays for medicines once generic competition exists, which is a major reason generics matter at a national level as well as an individual one.

Many medicines in the erectile dysfunction category are dispensed as private prescriptions rather than PBS-subsidised, which is exactly why the difference between brand and generic can be very visible at the counter. It is a reasonable thing to raise with your pharmacist.

Cheaper does not mean lower standard

This is where the distinction has to be sharp. A registered generic is cheaper because of what it did not have to pay for, not because of anything it skipped in quality. The same TGA standards apply to manufacturing, testing, batch consistency, adverse event reporting and recall.

When a low price is a warning sign

The economics above explain a moderate discount from a legitimate supplier. They do not explain a price that is a small fraction of everything else on the market, from a website that ships from overseas and asks no questions.

At that point the cost saving is coming from somewhere else: no regulatory evaluation, no quality assurance, no prescription requirement, no accountable business. The TGA has repeatedly warned that products bought this way can contain the wrong ingredient, the wrong amount, or contaminants. And if something goes wrong, Australian Consumer Law protections are of little practical use against a seller with no Australian presence.

A useful test: does the price make commercial sense for a product that was manufactured to pharmaceutical standards, tested, registered and distributed through a regulated chain? Sometimes yes. Sometimes obviously not.

The prescription requirement does not change

Price has no bearing on legal classification. Sildenafil, tadalafil, vardenafil and dapoxetine are Schedule 4 prescription-only medicines in Australia, generic or otherwise, and require a valid prescription from a registered Australian prescriber. A seller advertising a low price alongside no prescription needed is advertising two problems, not a bargain.

The clinical cautions are also unchanged by price. Nitrate medicines, including glyceryl trinitrate and isosorbide products and recreational nitrites, are an absolute contraindication. Caution applies with alpha-blockers and in significant cardiovascular disease. Chest pain, an erection lasting more than four hours, or sudden vision or hearing loss need urgent medical attention.

How to compare sensibly

• Compare like with like — same active ingredient and strength.
• Ask the pharmacy about the total cost including any dispensing fee.
• Ask whether the product is on the ARTG.
• Mention any allergies so excipients can be checked.
• If cost is a barrier to staying on a medicine, say so; there may be alternatives worth discussing with your prescriber.

This article is general information about medicine pricing and regulation, not medical advice. Speak with your doctor or pharmacist about your own treatment and costs.